Press Release: Dendreon Corporation (Nasdaq: DNDN) announced the following data presentations taking place at the American Urological Association's (AUA) Annual Meeting in Chicago, as well as a Dendreon-sponsored IMPACT data webcast conference call: (for those of us who will be unable to attend the session at AUA in Chicago) April 28, 2009, 2:20 p.m. CDT-"A [...]
As a follow up to yesterday's news about the positive results announced about Provenge, I have received a number of private emails asking questions about the treatment. I hope that the following will answer many of the questions people might still have about Provenge. • The other name for Provenge is sipuleucel-T. • Provenge is [...]
What great news has greeted us today. We can now hope that the FDA will quickly approve Provenge and we can get this sorely needed treatment ASAP. If Provenge gets approval from the FDA it will be the first cancer vaccine ever approved. Sadly it will be only the second approved treatment for prostate cancer! [...]
For those of us who believed that we are alone in the search for a prostate cancer vaccine for advanced prostate cancer, the good news is that we are not. The Vladimir Ilich Lenin hospital, located in Cuba, has announced that they will shortly begin the second phase of the clinical trial of a vaccine [...]
At 9 am this morning, Dendreon Corporation (Nasdaq: DNDN) announced the long awaited interim analysis of the Phase 3, randomized, double-blind, placebo-controlled IMPACT (Immunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B). The clinical trial is designed to assess the safety and efficacy of the investigational active cellular immunotherapy Provenge® (sipuleucel-T) in men with metastatic [...]
Dendreon Corporation (Nasdaq: DNDN), the company that is testing Provenge a potential vaccine for prostate cancer, has started a second of two new Phase 2 trials. The multicenter trial, called ProACT (PROstate Active Cellular Therapy), is enrolling 120 men with metastatic, androgen independent prostate cancer. The trial protocol calls for all men to receive active [...]
According to Philip M. Arlen, M.D., director of the Clinical Research Group for the Laboratory of Tumor Immunology and Biology, Center for Cancer Research, at the National Cancer Institute, "Vaccines, if and when they are approved, can be safely and effectively combined with other therapies, including hormones. There appears to be an advantage in overall [...]
Yesterday, Dendreon Corp (DNDN) announced that the FDA has agreed to allow them to amend the trial design of its Provenge cancer vaccine. The change in the design will accelerate the expected timing of the final study results by about one year. According to Dendreon, the interim results of the impact study are still expected [...]
I received an e-mail this morning from Leslie who was the producer and director of the short video I filmed about the Provenge issue at the FDA. (you can view the video at: Joel's Provenge Video Leslie asked that I sign a petition asking for a formal inquiry into the conflict of interest (COI) issues [...]
Today’s New York Times carried a story written by Reed Abelson entitled “Financial Ties Are Cited as Issue in Spine Study.” The story explained that some of the nation’s most prominent spine surgeons hailed as a medical breakthrough a study of nearly 240 patients with lower back pain. The doctors said that Prodisc, an artificial [...]
